(IN BRIEF) Sanofi has launched early global shipments of Beyfortus (nirsevimab) in anticipation of the 2025–2026 RSV season, enabling healthcare providers to begin immunizations well before the typical onset of infections in November. In collaboration with AstraZeneca, Sanofi has significantly … Read the full press release
Posted in Business, Financial, France, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged AstraZeneca, Beyfortus, EU label, extended protection, global distribution, hospitalizations, infant immunization, lower respiratory tract disease, monoclonal antibody, newborn care, nirsevimab, pediatric health, public health, real-world studies, respiratory syncytial virus, RSV, RSV season, Sanofi, Thomas Triomphe, Vaccine Innovation, vaccine supply chain
(IN BRIEF) At the 10th Open Meeting of the Spanish Network of Healthy Companies, Sener was recognized for its Sener Care programme and commitment to promoting workplace health. The award highlights Sener’s comprehensive health initiatives, including disease prevention, psychological support, … Read the full press release
Posted in Awards, Business, Financial, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, Marketing, Media, News, Spain, Technology
Tagged ADIF, Awards, Castilla-La Mancha, corporate health, disease prevention, Employee Wellbeing, health initiatives, healthy lifestyle habits, HSE, INSST, leadership, psychological support, Renfe, Sacyr, SENER, Sener Care, Spanish Heart Foundation, Spanish Network of Healthy Companies, workplace health, workplace safety
(IN BRIEF) AstraZeneca’s Calquence, in combination with venetoclax, with or without obinutuzumab, has been approved by the European Commission for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). The approval follows the positive results from the … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AMPLIFY Phase III trial, AstraZeneca, Barbara Eichhorst, BTK inhibitor, Calquence, chemoimmunotherapy, chronic lymphocytic leukaemia, clinical trial, CLL, Dave Fredrickson, European Commission approval, European Union, fixed-duration regimen, hematologic diseases, hematology, leukemia, obinutuzumab, oncology, progression-free survival, treatment option, venetoclax
(IN BRIEF) Dr. Steffen Knoblauch from Heidelberg University has developed a high-resolution environmental suitability map for the Aedes aegypti mosquito in Rio de Janeiro, using geospatial big data such as satellite imagery and climate data. The map, which models 79 … Read the full press release
Posted in Business, Education, Environment, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Science, Technology
Tagged Aedes aegypti, Austrian Science Fund, Brazil, chikungunya, climate data, Dengue, Dr. Steffen Knoblauch, environmental suitability map, GeoAI, Geospatial Artificial Intelligence, geospatial big data, German Research Foundation, Heidelberg University, HeiGIT, infectious diseases, IWR, mosquito breeding sites, Rio de Janeiro, satellite imagery, spatio-temporal modeling, The Lancet Planetary Health, urban heat island, urbanization, vector control, yellow fever, ZIKA
(IN BRIEF) SCHOTT Pharma has begun construction on a new production facility for ready-to-use (RTU) cartridges at its Lukácsháza site in Hungary. The investment of over 100 million euros will expand the company’s manufacturing capacity to meet increasing demand for … Read the full press release
Posted in Business, Environment, Financial, Germany, Government, Healthcare, Hungary, Industrial, Infrastructure & Utilities, Investment, Management, Marketing, News, Pharma & Biotech, Science, Technology
Tagged Andreas Reisse, biologics, Diabetes, Eva Szabó, expansion, GLP-1 drugs, high-value solutions, hormone therapies, Hungary, insulin, investment, Lukácsháza, manufacturing capacity, Ministry of Foreign Affairs and Trade, Obesity, partnership, pharmaceutical industry, pharmaceutical packaging, ready-to-use cartridges, SCHOTT Pharma, sterile cartridges, sustainability, sustainable development
(IN BRIEF) Fresenius Medical Care has received FDA 510(k) clearance for its updated 5008X CAREsystem with additional features, enabling the introduction of high-volume hemodiafiltration therapy across the U.S. This new therapy, proven to reduce mortality rates by 23% in patients, … Read the full press release
Posted in Business, Environment, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Science, Security & Safety, Technology
Tagged 5008X CAREsystem, CDX™, Clinical Data Exchange, CONVINCE study, FDA 510(k) clearance, Fresenius Kidney Care, Fresenius Medical Care, FX CorAL dialyzer, hemodialysis, high-volume hemodiafiltration, INNOVATION, kidney care, kidney disease treatment, mortality reduction, partnership, patient care, renal disease, U.S. rollout
(IN BRIEF) The Viessmann Foundation has donated €5.6 million to the German Cancer Research Center (DKFZ) to advance research into cancer prevention through nutrition and the development of new treatments for pediatric oncology. This five-year funding will support vital research … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Non Profit, Science, Technology
Tagged Cancer Prevention, cancer research, Cancer Therapies, DKFZ, donation, Fostering Future Generations, Healthcare, Max Viessmann, Michael Baumann, Nutrition, pediatric cancer treatments, pediatric oncology, Viessmann Foundation, Viessmann Generations Group
(IN BRIEF) SGS has acquired H2Safety, a leading Canadian provider of emergency management and operational safety solutions, to bolster its Health & Safety offering in North America. This acquisition expands SGS’s capabilities in key areas such as emergency management, business … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Security & Safety, Switzerland, Technology
Tagged acquisition, Business Continuity, certification, emergency management, H2Safety, Health & Safety, infrastructure protection, inspection, North America, operational safety, partnership, regulatory compliance, risk mitigation, safety services, SGS, sustainability, testing
(IN BRIEF) Roche announced the European Commission’s approval of a label extension for Evrysdi® (risdiplam) to include a new 5mg tablet, offering a room-temperature stable alternative to the original oral solution for individuals with spinal muscular atrophy (SMA). The tablet, … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Switzerland, Technology
Tagged 5mg tablet, bioequivalence, clinical development, clinical study, disease-modifying treatment, European Commission, Evrysdi, family caregivers, label extension, Nicole Gusset, non-invasive treatment, PTC Therapeutics, risdiplam, Roche, SMA, SMA Europe, SMA Foundation, SMA patients, SMN protein, spinal muscular atrophy, treatment flexibility
(IN BRIEF) The European Investment Bank (EIB) has signed a €20 million financing deal with Leyden Laboratories to support the development of its innovative pan-influenza nasal spray, which aims to protect against seasonal and pandemic viral infections. The funding, guaranteed … Read the full press release
Posted in Banks, Business, Economy, Environment, Financial, Government, Healthcare, Industrial, Investment, Luxembourg, Management, Marketing, Netherlands, News, Pharma & Biotech, Science, Technology
Tagged antiviral protection, avian flu, biodefense, EU4Health, European Commission, European health defense, European Investment Bank, Hadja Lahbib, HERA Invest, influenza, InvestEU, Koenraad Wiedhaup, Leyden Labs, nasal spray, non-vaccine approach, Pandemic Preparedness, partnership, respiratory viruses, Robert de Groot, sustainability
(IN BRIEF) Rilzabrutinib, an oral Bruton’s tyrosine kinase (BTK) inhibitor, has received orphan drug designation from the U.S. FDA for sickle cell disease. This marks the fourth such designation for the drug, which has already been recognized for its potential … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged BTK inhibitor, fast track status, FDA, IgG4-related disease, immune thrombocytopenia, multi-immune modulation, orphan drug designation, preclinical data, rare diseases, rilzabrutinib, Sanofi, sickle cell disease, Tailored Covalency®, vaso-occlusive crises, warm autoimmune hemolytic anemia
(IN BRIEF) A study by the University of Helsinki has uncovered why some breast cancer treatments, including immunotherapy, may not be effective for all patients. The research, focusing on the mechanical properties of tumor tissue, shows that softer tissue environments … Read the full press release
Posted in Business, Education, Financial, Finland, Healthcare, Industrial, Investment, Management, News, Science, Technology
Tagged breast cancer, cancer research, cancer treatment, Finland, global research collaboration, HUS Helsinki University Hospital, immunotherapy, Kymenlaakso Health, MD-PhD student Aino Peura, Nature Communications, personalized medicine, tissue microenvironment, tumor progression, University of Helsinki
(IN BRIEF) Researchers at Newcastle University have discovered a new biological mechanism explaining why some patients do not respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors. They identified T regulatory cells (Tregs) as key drivers of ICB … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged anti-CD30, Brentuximab Vedotin, Cancer Immunotherapy, cancer research, combination treatment, ICB resistance, immune checkpoint blockade, immunotherapy breakthroughs, lung cancer, melanoma, metastatic cancer, Newcastle University, pancreatic cancer, PD-1, skin cancer, solid tumors, T regulatory cells
(IN BRIEF) The University of Glasgow has appointed Professor Emma Thomson as the new Director of the MRC-University of Glasgow Centre for Virus Research (CVR), after she served as Interim Director from February. An expert in emerging infectious diseases, Professor … Read the full press release
Posted in Education, Healthcare, Science, Technology, United Kingdom
Tagged Centre for Virus Research, COVID-19, CVR, emerging viruses, Glasgow medical research, global health, hepatitis, infectious diseases, MRC, Pandemic Preparedness, Professor Emma Thomson, public health, scientific leadership, University of Glasgow, vaccine trials, viral research, virology
(IN BRIEF) Novartis has announced that its Phase III PSMAddition trial of Pluvicto™ in combination with standard of care (SoC) has met its primary endpoint, showing a significant benefit in radiographic progression-free survival (rPFS) and a positive trend in overall … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged androgen receptor pathway inhibitors, cancer research, clinical trials, FDA approval, FDA regulatory review, metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, mHSPC, Novartis, Novartis oncology, overall survival, Phase III PSMAddition, Pluvicto, progression-free survival, prostate cancer, prostate cancer treatment, PSMA-positive, radioligand therapy, treatment options
(IN BRIEF) Novartis has presented new data from the Phase III NATALEE trial at ASCO 2025, showcasing Kisqali’s ability to reduce the risk of recurrence in pre-menopausal patients with high-risk early breast cancer. The data reveals a 33% reduction in … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged adjuvant treatment, ASCO 2025, Black patients, Breast Cancer Treatment, CDK4/6 inhibitors, DDFS, disparities in healthcare, early breast cancer, EBC, endocrine therapy, HR+/HER2-, invasive disease-free survival, Kisqali®, metastatic breast cancer, Novartis, Phase III NATALEE, post-menopausal, pre-menopausal, recurrence-free survival, RFS, ribociclib, Risk Reduction, survival benefit
(IN BRIEF) Eckert & Ziegler successfully hosted the 3rd annual Boston Radionuclide Theranostics Forum, bringing together industry leaders to discuss radionuclide theranostics’ role in transforming precision oncology. The event featured expert presentations on advancements in radiopharmaceuticals, clinical development challenges, and … Read the full press release
Posted in Berlin, Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, Marketing, Media, News, Pharma & Biotech, Science, Technology
Tagged Boston Radionuclide Theranostics Forum, clinical development, Dr. Harald Hasselmann, Eckert & Ziegler, German American Business Council, Industry innovation, Morrison Foerster, nuclear medicine, patient access, precision oncology, radionuclide theranostics, radiopharmaceutical community, radiopharmaceuticals, radiotherapy, Solomon Partners
(IN BRIEF) Fresenius Medical Care will showcase a variety of new research at the 62nd Congress of the European Renal Association (ERA) in Vienna, focusing on advancements in kidney care, artificial intelligence, fluid management, and hemodiafiltration. Key studies include the … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Industrial, Investment, Management, Marketing, Media, News, Science, Technology
Tagged AI, Andrea Nandorine Ban, artificial intelligence, CONVINCE trial, dialysis, ERA Congress, fluid management, Frank Maddux, Fresenius Medical Care, hemodiafiltration, hemodialysis, kidney disease, medical advancements, nephrology, patient outcomes, Renal Research Institute, RESEARCH
(IN BRIEF) Roche presented promising 96-week data from the Phase II FENopta study, showing that its investigational drug, fenebrutinib, significantly reduced relapse rates and prevented disability progression in patients with relapsing multiple sclerosis (RMS). The study revealed an annualized relapse … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Bruton’s tyrosine kinase, BTK inhibitor, clinical data, clinical research, clinical trial, data, disability, disability progression, fenebrutinib, FENopta, Levi Garraway, multiple sclerosis, Phase II, relapse rates, relapsing multiple sclerosis, RMS, Roche, treatment
(IN BRIEF) Itepekimab, developed by Sanofi and Regeneron, met its primary endpoint in the AERIFY-1 phase 3 study for COPD, showing a 27% reduction in moderate or severe exacerbations at 52 weeks. However, the AERIFY-2 study did not achieve the … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Technology
Tagged adverse events, AERIFY-1, AERIFY-2, Chronic obstructive pulmonary disease, clinical trials, COPD, COVID-19, drug efficacy, Exacerbations, IL33, Itepekimab, moderate exacerbations, monoclonal antibody, partnership, phase 3 study, Regeneron, regulatory authorities, research and development, Sanofi, severe exacerbations, therapeutic development
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?